FDA approves ENFLONSIA, a long-acting monoclonal antibody to protect infants from RSV-related lung disease through their first winter with a single fixed-dose shot.

The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include people 18 to 59 years old who are at increased risk for severe illness from ...

The ACIP is recommending the use of Enflonsia for the prevention of RSV lower respiratory tract disease in infants younger than 8 months.

A second monoclonal antibody to prevent respiratory syncytial virus (RSV) in infants has been recommended by the CDC’s Advisory Committee on Immunization Practices (ACIP). Five members voted yes ...

Robert F. Kennedy Jr. had fired all 17 members of a key vaccine panel. Now his new panel recommended a new infant RSV vaccine. What to know.

A newly configured federal vaccine panel's June 25 action is expected to improve options to protect infants from potentially deadly RSV.

CDC advisers recommend Merck's Enflonsia to protect babies from RSV, addressing the leading cause of infant hospitalization ...

Gilead Sciences has blamed the low rate of respiratory syncytial virus (RSV) infections last season for ending two midstage trials of obeldesivir. | Gilead has blamed the low rate of respiratory ...

A newly configured federal vaccine panel's June 25 action is expected to improve options to protect infants from potentially deadly RSV.